CARLSBAD, Calif., Oct. 23, 2012 (GLOBE NEWSWIRE) -- Alphatec Holdings, Inc. (Nasdaq:ATEC), the parent company of Alphatec Spine, Inc., a medical device company that designs, develops, manufactures and markets products for the surgical treatment of spine disorders, with a focus on treating conditions related to the aging spine, announced today that it will showcase several new products at the upcoming North American Spine Society (NASS) meeting in Dallas, TX, which will be held from October 24th to 26th, 2012. Alphatec Spine will be located in booth number 1116.
This year's product showcase will include:
Trestle LuxeTM Anterior Cervical Plating System is the Company's next-generation anterior cervical fixation system. Trestle Luxe is a unique and easy to use system that incorporates a zero-step locking mechanism into one of the lowest profile plates available. Trestle Luxe incorporates a number of other beneficial features such as large windows that enable better graft site/end plate visualization, an assortment of screws that provide multiple fixation options, plus a comprehensive array of implants and instrumentation to meet surgeon needs.
BridgePoint™ Spinous Process Fixation System is Alphatec Spine's newest Minimally Invasive Surgery (MIS) device that is designed to enable spine surgeons to immobilize and stabilize spinal segments without the need for pedicle screw and rod constructs. The BridgePoint System is intended to be an adjunct to fusion of the thoracic and lumbar spine to treat disorders resulting from degenerative disc disease, spondylolisthesis, tumor and trauma. The device's state of the art design incorporates unique telescoping plates that allow users to compress the anterior column for a reliable interbody fusion, and its large bone contact area provides a strong anchor point from which to apply compression as well as optimal stability during the fusion process.
Alphatec NEXoss™, is a next-generation synthetic bone graft indicated for use in posterolateral spine fusions in conjunction with bone marrow aspirate, autograft bone and appropriate hardware. Alphatec NEXoss is composed of two unique patented technologies. The first is an engineered extracellular collagen bioscaffold that provides a physical structure for cell infiltration and attachment. The second is osteoconductive nano-structured bone crystals that have similar composition, structure and size as human bone. These two technologies function together to provide an ideal environment for a natural bone growth solution. Alphatec NEXoss is supported by in vitro and in vivo clinical data.
"We are pleased to highlight our newest products, as well as the entire Alphatec Spine product portfolio, at the 27th annual NASS meeting this month. We also look forward to meeting many surgeons, investors and analysts at NASS," said Les Cross, Chairman and Chief Executive Officer of Alphatec Spine. "Each new product represents the latest in our technology and provides unique benefits that deliver real value to surgeons, hospitals and patients. Our strategy is to deliver a continuous stream of new products that are focused on minimally invasive techniques and Biologics solutions into an expanding geographical footprint. We are proud to play a role in helping patients who suffer from spinal disorders and chronic pain, regain their active lifestyles."
In addition, on Thursday, October 25 at 10:00 am in Hall B, Alphatec Spine will participate in the NASS Solution Showcase and will present "Introducing Trestle Luxe Anterior Cervical Plating and Initial Clinical Experience". The Company will also offer interactive Sawbones Workshops at its booth (booth #1116) during exhibit hours.
About Alphatec Spine
Alphatec Spine, Inc. is a wholly owned subsidiary of Alphatec Holdings, Inc. (Nasdaq:ATEC). Alphatec Spine is a medical device company that designs, develops, manufactures and markets products for the surgical treatment of spine disorders, primarily focused on the aging spine. The Company's mission is to combine world-class customer service with innovative, surgeon-driven products that will help improve the aging patient's quality of life. The Company is poised to achieve its goal through new solutions for patients with osteoporosis, stenosis and other aging spine deformities, improved minimally invasive products and techniques and integrated biologics solutions. In addition to its U.S. operations, the Company also markets its products in over 50 international markets through its affiliate, Scient'x S.A.S., via a direct sales force in France, Italy and the United Kingdom and via independent distributors in the rest of Europe, the Middle East and Africa. In Latin America, the Company conducts its business through its subsidiary, Cibramed Produtos Medicos. In Japan, the Company markets its products through its subsidiary, Alphatec Pacific, Inc. In the rest of Asia and Australia, the Company sells its and Scient'x's products through its and Scient'x's distributors.
The Alphatec Holdings, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=3520
Forward Looking Statements
This press release may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainty. Such statements are based on management's current expectations and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Alphatec Spine cautions investors that there can be no assurance that actual results or business conditions will not differ materially from those projected or suggested in such forward-looking statements as a result of various factors. Forward-looking statements include references to the Company's belief that certain of its products offer competitive functionalities in the marketplace. In addition, forward-looking statements include the Company's ability to develop and commercialize new products in MIS. The words "believe," "will," "should," "expect," "intend," "estimate" and "anticipate," variations of such words and similar expressions identify forward-looking statements, but their absence does not mean that a statement is not a forward-looking statement. The important factors that could cause actual operating results to differ significantly from those expressed or implied by such forward-looking statements include, but are not limited to; the uncertainty of success in developing or acquiring and commercializing new products or product technologies; acceptance of Alphatec Spine's products by the surgeon community; failure to successfully implement streamlining activities to create operating cost savings; failure to successfully begin in-house manufacturing of certain products; failure to obtain or maintain FDA clearance or approval for new products or technologies, including the product discussed in this press release, or unexpected or prolonged delays in the process; Alphatec Spine's ability to develop and expand its U.S. and/or global revenues; continuation of favorable third part payor reimbursement for procedures performed using Alphatec Spine's products; unanticipated expenses or liabilities or other adverse events affecting cash flow or Alphatec Spine's ability to successfully control its costs or achieve profitability; uncertainty of additional funding; Alphatec Spine's ability to compete with other competing products and with emerging new technologies; product liability exposure; failure to meet all financial obligations in the Cross Medical Settlement; patent infringement claims and claims related to Alphatec Spine's intellectual property. Please refer to the risks detailed from time to time in Alphatec Spine's SEC reports, including its Annual Report Form 10-K, as well as other filings on Form 10-Q and periodic filings on Form 8-K. Alphatec Spine disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, unless required by law.